Mounjaro

Eli Lilly launches Mounjaro in India for obesity and diabetes treatment

Global pharmaceutical company Eli Lilly has launched Mounjaro (tirzepatide) in India, a groundbreaking drug designed for the treatment of Type 2 diabetes and obesity. Approved by the Central Drugs Standard Control Organization (CDSCO), Mounjaro is now available in single-dose vials, with pricing set at Rs 3,500 for a 2.5 mg vial and Rs 4,375 for a 5 mg vial. The estimated monthly cost of treatment ranges between Rs 14,000 and Rs 17,500, depending on the dosage prescribed. Eli Lilly claims that...

July 9, 2024 4:57 PM

Novo Nordisk shares down after analysis finds Lilly drug leads to better weight loss

Shares in Novo Nordisk, maker of the wildly popular obesity drug Wegovy were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly's own treatment Mounjaro leads to faster and greater weight loss. The analysis was published on Monday in JAMA Internal Medicine, a medical journal. It examined health records and other data to assess the pace and percentage of weight loss for overweight and obese people taking tirzepatide - the active ingredient in Lilly's Mounjaro a...